Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives
Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy. Cutaneous side effects due to treatment with durvalumab are usually self-limiting and easily manageable. We pr...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-08-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/9/1062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850260581303451648 |
|---|---|
| author | Gyula Laszlo Fekete Laszlo Barna Iantovics Júlia Edit Fekete Laszlo Fekete |
| author_facet | Gyula Laszlo Fekete Laszlo Barna Iantovics Júlia Edit Fekete Laszlo Fekete |
| author_sort | Gyula Laszlo Fekete |
| collection | DOAJ |
| description | Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy. Cutaneous side effects due to treatment with durvalumab are usually self-limiting and easily manageable. We present a clinical case of a female patient aged 61, with small-cell lung carcinoma in stage III B, cT3N2M, who developed a disseminated cutaneous vasculitis after seven months of durvalumab monotherapy, having previously been treated with polychemotherapy according to oncological protocols. To the best of our knowledge, based on a comprehensive search in leading databases, like Web of Science, Scopus, PubMed and some others, ours is the first published case of disseminated cutaneous vasculitis as a result of Durvalumab treatment. Anticancer immunotherapy targeting immune checkpoint inhibition (ICI) has transformed the treatment and evolution of patients with multiple varieties of hematologic cancers. In this context, the cutaneous side effects due to immune checkpoint inhibitor therapies are very few in the scientific literature. Based on this need, we have performed a mini-review of cutaneous side effects due to immune checkpoint inhibitor therapies that treat actual aspects in this sense. We also present some artificial intelligence challenges and future perspectives in the combination of human reasoning and reasoning based on Artificial Intelligence for study of the very rare Disseminate cutaneous vasculitis associated with Durvalumab treatment. |
| format | Article |
| id | doaj-art-e2d5b61eaf2546089f6dbe724d5834bc |
| institution | OA Journals |
| issn | 2075-1729 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-e2d5b61eaf2546089f6dbe724d5834bc2025-08-20T01:55:37ZengMDPI AGLife2075-17292024-08-01149106210.3390/life14091062Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning PerspectivesGyula Laszlo Fekete0Laszlo Barna Iantovics1Júlia Edit Fekete2Laszlo Fekete3Department of Dermatology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, RomaniaDepartment of Electrical Engineering and Information Technology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, RomaniaNational Institute of Public Health, Regional Center for Public Health, 540142 Targu Mures, RomaniaCMI Dermamed Private Medical Office, 540530 Targu Mures, RomaniaDurvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy. Cutaneous side effects due to treatment with durvalumab are usually self-limiting and easily manageable. We present a clinical case of a female patient aged 61, with small-cell lung carcinoma in stage III B, cT3N2M, who developed a disseminated cutaneous vasculitis after seven months of durvalumab monotherapy, having previously been treated with polychemotherapy according to oncological protocols. To the best of our knowledge, based on a comprehensive search in leading databases, like Web of Science, Scopus, PubMed and some others, ours is the first published case of disseminated cutaneous vasculitis as a result of Durvalumab treatment. Anticancer immunotherapy targeting immune checkpoint inhibition (ICI) has transformed the treatment and evolution of patients with multiple varieties of hematologic cancers. In this context, the cutaneous side effects due to immune checkpoint inhibitor therapies are very few in the scientific literature. Based on this need, we have performed a mini-review of cutaneous side effects due to immune checkpoint inhibitor therapies that treat actual aspects in this sense. We also present some artificial intelligence challenges and future perspectives in the combination of human reasoning and reasoning based on Artificial Intelligence for study of the very rare Disseminate cutaneous vasculitis associated with Durvalumab treatment.https://www.mdpi.com/2075-1729/14/9/1062small-cell lung cancercancerimmunotherapydurvalumabvasculitiscutaneous side effect |
| spellingShingle | Gyula Laszlo Fekete Laszlo Barna Iantovics Júlia Edit Fekete Laszlo Fekete Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives Life small-cell lung cancer cancer immunotherapy durvalumab vasculitis cutaneous side effect |
| title | Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives |
| title_full | Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives |
| title_fullStr | Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives |
| title_full_unstemmed | Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives |
| title_short | Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives |
| title_sort | disseminate cutaneous vasculitis associated with durvalumab treatment case report mini review on cutaneous side effects of immune checkpoint inhibitor therapies with machine learning perspectives |
| topic | small-cell lung cancer cancer immunotherapy durvalumab vasculitis cutaneous side effect |
| url | https://www.mdpi.com/2075-1729/14/9/1062 |
| work_keys_str_mv | AT gyulalaszlofekete disseminatecutaneousvasculitisassociatedwithdurvalumabtreatmentcasereportminireviewoncutaneoussideeffectsofimmunecheckpointinhibitortherapieswithmachinelearningperspectives AT laszlobarnaiantovics disseminatecutaneousvasculitisassociatedwithdurvalumabtreatmentcasereportminireviewoncutaneoussideeffectsofimmunecheckpointinhibitortherapieswithmachinelearningperspectives AT juliaeditfekete disseminatecutaneousvasculitisassociatedwithdurvalumabtreatmentcasereportminireviewoncutaneoussideeffectsofimmunecheckpointinhibitortherapieswithmachinelearningperspectives AT laszlofekete disseminatecutaneousvasculitisassociatedwithdurvalumabtreatmentcasereportminireviewoncutaneoussideeffectsofimmunecheckpointinhibitortherapieswithmachinelearningperspectives |